Business
Borregaard ASA: EBITDA1 of NOK 405 million in the 4th quarter 2025
Borregaard’s operating revenues increased to NOK 1,833 million (NOK 1,744 million)2 in the 4th quarter of 2025. EBITDA1 was NOK 405 million (NOK 398 million). The result in BioMaterials increased, while BioSolutions and Fine Chemicals had lower results compared with the 4th quarter of 2024. In BioSolutions, high deliveries of biovanillin and sustained growth in sales to agriculture were more than offset by increased costs. For BioMaterials, higher sales prices and lower wood and energy costs, mo
About this update from Borregaard Asa
[{"type":"image","alt":"Borregaard","displaySize":"","headline":null,"caption":"Borregaard","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":37,"url":"https://media.zenfs.com/en/globenewswire.com/3ca471c24cf8d614d856c20a5fb1d45c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/giUvSxNgzauHnuW27hHM2g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTUyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/3ca471c24cf8d614d856c20a5fb1d45c","width":150,"height":37}},"lazy":false},{"type":"text","content":"Borregaard’s operating revenues increased to NOK 1,833 million (NOK 1,744 million)2 in the 4th quarter of 2025. EBITDA1 was NOK 405 million (NOK 398 million). The result in BioMaterials increased, while BioSolutions and Fine Chemicals had lower results compared with the 4th quarter of 2024.","length":291,"tagName":"p"},{"type":"text","content":"In BioSolutions, high deliveries of biovanillin and sustained growth in sales to agriculture were more than offset by increased costs. For BioMaterials, higher sales prices and lower wood and energy costs, more than compensated for other cost increases. For Fine Chemicals, lower bioethanol sales prices were partly offset by a strong result for fine chemical intermediates. Net currency effects were slightly positive for the Group.","length":433,"tagName":"p"},{"type":"text","content":"In the 4th quarter of 2025, Borregaard has made a total impairment of NOK 245 million of its investments in the bio-based start-ups Alginor ASA, Kaffe Bueno ApS and Lignovations GmbH to reflect recent development in these companies. The impairment is recorded as part of financial items.","length":287,"tagName":"p"},{"type":"text","content":"Profit before tax was NOK -28 million (NOK 170 million). Earnings per share were NOK -0.81 (NOK 1.30). Excluding impairments of bio-based start-ups, earnings per share were NOK 1.64.","length":182,"tagName":"p"},{"type":"text","content":"Full year 2025Operating revenues increased to NOK 7,713 million (NOK 7,617 million) in 2025. EBITDA1 was NOK 1,878 million (NOK 1,874 million), an all-time high result. BioSolutions and BioMaterials had improved results, while Fine Chemicals had a decrease compared with 2024. Profit before tax was NOK 864 million (NOK 1,079 million). Earnings per share were NOK 6.22 (NOK 8.25). Excluding impairments of bio-based start-ups, earnings per sha...